Interestingly, however, when SCLC cells are plated on laminin, resistance to apoptosis is induced by imatinib because of the laminin-mediated increased activation of the mTOR pathway [45], which may contribute to the failure of phase 2 clinical trial [31,32,33]. Here, MTOR is linked to small cell lung carcinoma.